NCT06548997View on ClinicalTrials.gov

A Phase I Study of GZR18 Injection in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

October 20, 2022

Study Completion Date

October 20, 2022

Conditions
Type 2 DiabetesOverweight and Obesity
Interventions
DRUG

GZR18

5 μg/kg-maximum tolerated dose (MTD), single dose or two doses

OTHER

Placebo

administered the same volume as GZR18

Trial Locations (1)

Unknown

Gan & Lee Pharmaceuticals Co., Ltd, Beijing

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY